Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Antonio, Texas 78229


Purpose:

The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.


Study summary:

Only patients with 0 to 1 performance status on the ECOG scale are eligible.


Criteria:

Inclusion Criteria: - Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or cytological). - Received prior chemotherapy treatment for advanced, metastatic non-small cell lung cancer. - Measurable disease per RECIST criteria. - Adequate bone marrow, hepatic and renal function. Exclusion Criteria: - Breast cancer or skin cancer at any time in the past or any other cancer in the past 5 years. - Brain metastases that are unstable, require steroids, are life-threatening or required radiation in the last 28 days. - Known hypersensitivity to minocycline. - History of serious cardiac disease that is not controlled. - Serious eye conditions. - Prior treatment with inhibitors of EGFR of any kind.


NCT ID:

NCT00072631


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

San Antonio, Texas 78229
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 11, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.